Stallergenes group

For 50 years, Stallergenes, specialized in the treatment of severe respiratory allergies, has set itself the goal of working alongside health professionals to improve the management of severe respiratory allergies and ensure a long-term improvement in patients’ quality of life.

A biopharmaceutical company expert and leader on its market
Its activities include research & development, as well as marketing of allergen immunotherapy treatments against severe respiratory allergies.

The key to Stallergenes’ know-how – in terms of product development, raw material quality or the extraction and production process – lies in its knowledge of allergens. Drawing on this expertise, the biopharmaceutical company works constantly to improve its products.

Every year, almost 500 000 patients benefit from the biopharmaceutical company’s treatments, which curb the progression of the disease.¹

Today, Stallergenes is the world leader on the sublingual immunotherapy market, having enjoyed average annual growth of 14% since 2000.

[1] Bousquet J, Lockey RF, Malling HJ. et al. Allergy 1998; 53

Contact us